Table 25All-Cause Mortality Among Selenium Studies

StudyComparisonMean followup (y)Intervention, # of deaths (%)Comparator, # of deaths (%)RR or HR95% CIP-value
NPC89,92,173Selenium vs. placebo6108/653 (16.5)129/659 (19.6)0.830.63 to 1.080.14
7.6110/504 (21.8)110/500 (22)0.95§0.73 to 1.240.71
SELECT82Selenium vs. placebo5378/8,752 (4.3)382/8,696 (4.4)0.99*0.82 to 1.19NR
12551/8,752 (6.3)564/8,696 (6.5)0.98*0.84 to 1.140.67
Selenium + vitamin E vs. placebo5359/8,703 (4.2)382/8,696 (4.4)0.94*0.77 to 1.13NR
12542/8,703 (6.2)564/8,696 (6.5)0.96*0.82 to 1.120.47
*

HR; analyses did not incorporate adjustments for baseline covariates.

Noncardiovascular mortality also reported.

Unadjusted.

§

HR; adjusted for age, sex, and smoking status at baseline.

99% CI reported.

Abbreviations: CI = confidence interval; HR = hazard ratio; NPC = Nutritional Prevention of Cancer; NR = not reported; RR = relative risk; SELECT = Selenium and Vitamin E Cancer Prevention Trial;y = years.

From: 3, Results

Cover of Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer
Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 108.
Fortmann SP, Burda BU, Senger CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.